Gestor Editorial

Nuevo Usuario
Revisiones en Cáncer 00069 / http://dx.doi.org/10.20960/revcancer.00069
Resumen| PDF

Revisión

Carcinoma de cabeza y cuello en pacientes no candidatos a platino

Zara Vidales Sepúlveda, Marc Oliva Bernal

Prepublicado: 2024-03-21
Publicado: 2024-07-03
VOLUMEN 38, NÚM. 2, marzo-abril (2024), PAG. 60-69

Logo Descargas   Número de descargas: 45580      Logo Visitas   Número de visitas: 1046      Citas   Citas: 0

Compártelo:


El cisplatino es un componente esencial del tratamiento del carcinoma escamoso de cabeza y cuello, tanto en la enfermedad localmente avanzada como en la recurrente/metastásica. Sin embargo, la toxicidad aguda y crónica del cisplatino no es asumible en todos los pacientes; está contraindicado absoluta o relativamente en diferentes situaciones clínicas. A lo largo de este trabajo se resume la evidencia disponible de combinaciones libres de cisplatino para el tratamiento de la enfermedad en fase localmente avanzada y en fase recurrente-metastásica.

Palabras Clave: Inelegible para cisplatino. Frágil. Tratamiento adaptado.



Ahn MJ, D’Cruz A, Vermorken JB, Chen JP, Chitapanarux I, Dang HQT, et al. Clinical recommendations for defining platinum unsuita- ble head and neck cancer patient populations on chemoradiother- apy: A literature review. Oral Oncol 2016;53:10-6.
DOI: 10.1016/j.oraloncology.2015.11.019
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet (London, England) 2013;381(9868):752-62.
DOI: 10.1016/S0140-6736(12)62167-9
Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 2004;22(2):262-8.
DOI: 10.1200/JCO.2004.08.039
Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH- NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol 2021;156:281-93.
DOI: 10.1016/j.radonc.2021.01.013
Ward MC, Reddy CA, Adelstein DJ, Koyfman SA. Use of systemic therapy with definitive radiotherapy for elderly patients with head and neck cancer: A National Cancer Data Base analysis. Cancer 2016;122(22):3472-83.
DOI: 10.1002/cncr.30214
Mayer A, Wenzel W, Wollschläger D, Bostel T, Krüger M, Matthias C, et al. Adjuvant chemoradiotherapy in elderly patients with head and neck cancer: a monoinstitutional, two-to-one pair-matching analysis. Strahlentherapie und Onkol 2022;198(2):159-70.
DOI: 10.1007/s00066-021-01890-2
Smile TD, Reddy CA, Matia B, Fleming CW, Domb C, Geiger JL, et al. A Reappraisal of Definitive Chemoradiotherapy for Older Adults with Advanced Head and Neck Cancer. Anticancer Res 2022;42(8):3845-52.
DOI: 10.21873/anticanres.15875
Falco A, de Oliveira TB, Cacicedo J, Ospina AV, Ticona MÁ, Galin- do H, et al. Ibero-american expert consensus on squamous cell carcinoma of the head and neck treatment in patients unable to receive cisplatin: Recommendations for clinical practice. Cancer Manag Res 2021;13:6689-703.
DOI: 10.2147/CMAR.S322411
Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H, et al. Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: Secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol 2015;10(1):1-7.
DOI: 10.1186/s13014-014-0319-y
De Castro G, Alves GV, Castro AF, Chaves ALF, De Marchi P, de Oliveira TB, et al. Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts. Crit Rev Oncol Hematol 2018;131:30-4.
DOI: 10.1016/j.critrevonc.2018.08.009
Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc 2016;91(3):386-96.
DOI: 10.1016/j.mayocp.2015.12.017
Bakas AT, Polinder-Bos HA, Streng F, Mattace-Raso FUS, Ziere G, de Jong RJB, et al. Frailty in Non-geriatric Patients with Head and Neck cancer. Otolaryngol - Head Neck Surg (United States) 2023;169(5):1215-24.
DOI: 10.1002/ohn.388
Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: A systematic review. Ann Oncol 2015;26(6):1091-101.
DOI: 10.1093/annonc/mdu540
Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 2014;32(24):2595-603.
DOI: 10.1200/JCO.2013.54.8347
Goede V. Frailty and Cancer: Current Perspectives on Assessment and Monitoring. Clin Interv Aging 2023;18:505-12.
DOI: 10.2147/CIA.S365494
Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, et al. Screening tools for multidimensional health problems war- ranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol Off J Eur Soc Med Oncol 2015;26(2):288-300.
DOI: 10.1093/annonc/mdu210
Swartz LK, Swiecicki PL. Head and Neck Cancers. Oncol Board Rev Bluepr Study Guid. Q&A Third Ed; 2021. p. 185-95.
Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(11):1462-75.
DOI: 10.1016/j.annonc.2020.07.011
Mesia R, Iglesias L, Lambea J, Martínez-Trufero J, Soria A, Taberna M, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2020). Clin Transl Oncol 2021;23(5):913-21.
DOI: 10.1007/s12094-020-02533-1
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French head and neck oncology and radio- therapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22(1):69-76.
DOI: 10.1200/JCO.2004.08.021
Li Q, Guan J, Zhang Y, Chen M, Li L, Xiao N, et al. A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). J Clin Oncol 2015;33(Suppl.15):6036-6036.
DOI: 10.1200/jco.2015.33.15_suppl.6036
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21-8.
DOI: 10.1016/S1470-2045(09)70311-0
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019;393(10166):51-60.
DOI: 10.1016/S0140-6736(18)32752-1
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human pap- illomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet (Lon- don, England) 2019;393(10166):40-50.
DOI: 10.1016/S0140-6736(18)32779-X
Patil VM, Noronha V, Menon N, Singh A, Ghosh-Laskar S, Budrukkar A, et al. Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients with Head and Neck Cancer, Unsuit- able for Cisplatin-Based Chemoradiation. J Clin Oncol Off J Am Soc Clin Oncol 2023;41(13):2350-61.
DOI: 10.1200/JCO.22.00980
Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankiv- ell M, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol 2017;18(9):1221-37.
DOI: 10.1016/S1470-2045(17)30458-8
Weiss J, Gilbert J, Deal AM, Weissler M, Hilliard C, Chera B, et al. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresecta- ble squamous cell carcinoma of the head and neck. Oral Oncol 2018;84:46-51.
DOI: 10.1016/j.oraloncology.2018.06.028
Martínez-Trufero J, Lozano Borbalas A, Pajares Bernad I, Taberna Sanz M, Ortega Izquierdo E, Cirauqui Cirauqui B, et al. Sequential chemotherapy regimen of induction with panitumumab and pacl- itaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum deriv- atives. The phase II, PANTERA/TTCC-2010-06 study. Clin Transl Oncol 2021;23(8):1666-77.
DOI: 10.1007/s12094-021-02567-z
Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, et al. Effect of standard radiotherapy with cisplatin vs accelerated radi- otherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma a randomized clinical trial. JAMA Oncol 2017;3(2):220-6.
DOI: 10.1001/jamaoncol.2016.4510
Patil VM, Noronha V, Joshi A, Muddu VK, Dhumal S, Arya S, et al. Weekly chemotherapy as Induction chemotherapy in local- ly advanced head and neck cancer for patient’s ineligible for 3 weekly maximum tolerable dose chemotherapy. Indian J Cancer 2014;51(1):20-4.
DOI: 10.4103/0019-509X.134608
Shirasu H, Yokota T, Kawakami T, Hamauchi S, Onozawa Y, Ogawa H, et al. Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unre- sectable head and neck cancer patient’s ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil. Int J Clin Oncol 2020;25(11):1914-20.
DOI: 10.1007/s10147-020-01742-6
Marín-Jiménez JA, Oliva M, Peinado Martín P, Cabezas-Camarero S, Plana Serrahima M, Vázquez Masedo G, et al. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locore- gionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy. Front Oncol 2022;12:1-10.
DOI: 10.3389/fonc.2022.953020
Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol 2014;32(23):2486-95.
DOI: 10.1200/JCO.2013.53.9163
Ngamphaiboon N, Chairoungdua A, Dajsakdipon T, Jiarpinitnun C. Oral Oncology 2023;145.
DOI: 10.1016/j.oraloncology.2023.106520
Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, et al. Pembroli- zumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol 2023;34(1):101-10.
DOI: 10.1016/j.annonc.2022.10.006
Bourhis J, Tao Y, Sun X, Sire C, Martin L, Liem X, et al. LBA35 Ave- lumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial. Ann Oncol 2021;32(I):S1310.
DOI: 10.1016/j.annonc.2021.08.2112
Thomson DJ, Slevin NJ, Baines H, Betts G, Bolton S, Evans M, et al. Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy with Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIM- RAD). Int J Radiat Oncol Biol Phys 2023;S0360-3016(23)08184-1.
Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, et al. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin cancer Res an Off J Am Assoc Cancer Res 2018;24(20):4949-59.
DOI: 10.1158/1078-0432.CCR-18-0467
Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med 2008;359(11):1116-27.
DOI: 10.1056/NEJMoa0802656
Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375(19):1856-67.
DOI: 10.1056/NEJMoa1602252
Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab Alone or with Chemotherapy for Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma in KEY- NOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol 2022;40(21):2321-32.
DOI: 10.1200/JCO.21.02198
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taber- na M, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, ran- domised, phas. Lancet Oncol 2021;22(4):463-75.
DOI: 10.1016/S1470-2045(20)30755-5
Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, et al. Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. Int J Clin Oncol 2021;26(3):494-506.
DOI: 10.1007/s10147-020-01829-0
Thapa DA, Cowell DA, Peters DA, Noble DDJ, James DA, Lamb DC, et al. The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pem- brolizumab-chemotherapy combination in Scotland. Clin Oncol (R Coll Radiol) 2024:S0936-6555(24)00071-2.
DOI: 10.1101/2023.06.08.23290541
Wu Q, Wang Q, Tang X, Xu R, Zhang L, Chen X, et al. Correlation between patients’ age and cancer immunotherapy efficacy. Oncoimmunology 2019;8(4):1-9.
Gomes F, Lorigan P, Woolley S, Foden P, Burns K, Yorke J, et al. A prospective cohort study on the safety of checkpoint inhibi- tors in older cancer patients – the ELDERS study. ESMO Open 2021;6(1):100042.
DOI: 10.1016/j.esmoop.2020.100042
Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernández JJ. Phase II study of the combination of cetux- imab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012;23(4):1016-22.
DOI: 10.1093/annonc/mdr367
Rubió-Casadevall J, Cirauqui Cirauqui B, Martínez Trufero J, Plana Serrahima M, García Castaño A, Carral Maseda A, et al. TTCC- 2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck. Front Oncol 2023;13:1-14.
DOI: 10.3389/fonc.2023.1226939
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuxi- mab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915-28.
DOI: 10.1016/S0140-6736(19)32591-7
Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, et al. Pembrolizumab With or Without Chemotherapy in Recur- rent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol 2023;41(4):790-802.
DOI: 10.1200/JCO.21.02508
Dzienis MR, Cundom JE, Fuentes CS, Hansen AR, Nordlinger MJ, Pastor AV, et al. 651O Pembrolizumab (pembro) + carboplatin (car- bo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/met- astatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study. Ann Oncol 2022;33:S839-40.
DOI: 10.1016/j.annonc.2022.07.775
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, et al. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol 2023;41(12):2166-80.
DOI: 10.1200/JCO.22.00332
Psyrri A, Fayette J, Harrington K, Gillison M, Ahn MJ, Takahashi S, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squa- mous cell carcinoma of the head and neck: KESTREL, a rand- omized, open-label, phase III study. Ann Oncol 2023;34(3):262-74.
DOI: 10.1016/j.annonc.2022.12.008
Fayette J, Licitra LFL, Harrington KJ, Haddad R, Siu LL, Liu YC, et al. 854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monal- izumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previous- ly treated with an immune checkpoint inhibitor (ICI). Ann Oncol 2023;34:S554-5.
DOI: 10.1016/j.annonc.2023.09.2000
Kong AH, Klein Hesselink MS, Aguilera B, Adkins D, Even C, Fayette J, et al. Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy. J Clin Oncol 2023;41(Suppl.16):6028-6028.
DOI: 10.1200/JCO.2023.41.16_suppl.6028
Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-la- bel, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol 2021;22(6):883-92.
DOI: 10.1016/S1470-2045(21)00136-4
Bauman J, Cancer GW. 2024 Multidisciplinary Head and Neck Cancers 2024 Multidisciplinary Head and Neck Cancers Sympo- sium; 2024.
Melero I, Castanon E, Álvarez M, Champiat S, Marabelle A. Intra- tumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol 2021;18(9):558-76.
DOI: 10.1038/s41571-021-00507-y
Fayette J, Cropet C, Gautier J, Toullec C, Burgy M, Bruyas A, et al. Results of the multicenter phase II FRAIL-IMMUNE trial evaluat- ing the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/ metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies. J Clin Oncol 2023;41(Suppl.16):6003-6003.
DOI: 10.1200/JCO.2023.41.16_suppl.6003

Revisión: Evaluación geriátrica del paciente oncológico

Publicado: 2022-07-26 / http://dx.doi.org/
Resumen | PDF

Revisión: Cáncer ginecológico en la anciana

Publicado: 2022-07-28 / http://dx.doi.org/
Resumen | PDF

Artículos más populares


Editado en Madrid por:
Diseño y Desarrollo web Im3diA comunicación

Una cookie o galleta informática es un pequeño archivo de información que se guarda en su navegador cada vez que visita nuestra página web. La utilidad de las cookies es guardar el historial de su actividad en nuestra página web, de manera que, cuando la visite nuevamente, ésta pueda identificarle y configurar el contenido de la misma en base a sus hábitos de navegación, identidad y preferencias. Las cookies pueden ser aceptadas, rechazadas, bloqueadas y borradas, según desee. Ello podrá hacerlo mediante las opciones disponibles en la presente ventana o a través de la configuración de su navegador, según el caso. En caso de que rechace las cookies no podremos asegurarle el correcto funcionamiento de las distintas funcionalidades de nuestra página web. Más información en el apartado “POLÍTICA DE COOKIES” de nuestra página web.

Rechazar